VCNX News and Press, Vaccinex Inc. From 02/23/21

Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...

Palm Beach, FL –February 23, 2021 – In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therapy includes using gene...

ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Surface Oncology will be exer...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Vaccinex, Inc Surges After Announcing Two Mulit-Project Deals with Leading Pharmaceutical Companies ” Vaccinex, Inc. (NASDAQ: VCNX) skyrocke...

Gainers: Vaccinex (VCNX) +106%.Evolus (EOLS) +75%.Energous (WATT) +45%.Viomi Technology (VIOT) +44%.Casa Systems (CASA) +42%.Canaan (CAN) +40%.JMP Group (JMP) +39%.Renren (RENN) +37%.The9 (NCTY) +32%.Forest Road Acquisition (FRX) +26%.Losers: China SXT Pharmaceuticals (SXT...

Vaccinex (VCNX) has announced the signing of multi-project deals with two undisclosed prominent pharmaceutical companies.The collaborations will focus on using ActivMAb, Vaccinex’s antibody discovery and novel viral display platform, for antibody discovery against complex antigens such...

ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of multi-project deals...

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10...

Vaccinex (VCNX): Q3 GAAP EPS of -$0.44 misses by $0.01.Revenue of $0.05M (-87.5% Y/Y)Press Release For further details see: Vaccinex EPS misses by $0.01

Addition al data from SIGNAL Huntington’s disease (HD) trial support continued development in H D and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA ® in Advanced, Recu...